Skip to content
Queen Creek Hip Help
Terms decoded · evidence measured · routes mapped

Queen Creek Hip Help

What do Queen Creek readers ask about a sore hip?

Which sore-hip questions deserve a straight answer?

Queen Creek's ordinary errands can mean a long spell in the car. A stiff hip may hurt when you stand after the drive.

Start with where the ache sits and what motion sets it off. Those details can matter more than a treatment name.

I'd begin with the question that affects tonight or tomorrow's walk. You don't need a lecture when the hip already hurts.

For clinic care, QC Kinetix offers non-surgical regenerative treatment: after an exam, licensed staff called medical providers can prepare blood or marrow—soft tissue held inside your bones—and deliver it by needle to the aching joint or nearby tendon, hoping to ease soreness.

Why does my hip hurt in the groin?

Groin soreness often comes from the hip joint, especially when you turn the leg or rise. That isn't a diagnosis, so an exam makes sense if the ache lingers or worsens.

Why does the outside of my hip hurt in bed?

Outer-hip soreness often involves a tendon, the tough cord joining muscle to bone. Lying on that side can press it, though an exam can check other causes.

What can I try at home?

Do less of a motion that brings a sharp ache, then try shorter periods of activity. You don't need bed rest, and your own doctor can help with medicine choices.

What is PRP for hip soreness?

PRP stands for platelet-rich plasma, the liquid part of your blood holding extra platelets, tiny pieces that help it clot. The clinic separates that liquid and places it by needle into the sore joint or beside a tendon, but research can't predict your result.

How much can a blood-based hip procedure cost in Arizona?

Cost isn't fixed because the material, preparation, visits, and follow-up differ. Ask for the full price in writing so a later fee doesn't surprise you.

Where is the nearest clinic route from Queen Creek?

The nearby office is west in Chandler near the Dobson Road interchange with Loop 202. If you're near Meridian or Ironwood, SR 24 may connect with Loop 202.

Sources

  1. Arnold Caplan, who NAMED mesenchymal stem cells more than 25 years earlier, argued in Stem Cells Translational Medicine that the name should be changed. His stated reason is exactly the marketing problem: because MSCs are called 'stem cells', patients infer they will receive direct medical benefit, imagining the cells will differentiate into regenerating tissue-producing cells - and hundreds of clinics and trials now use human MSCs with very few focusing on the in vitro multipotential capacities the name refers to.

    Caplan AI, et al. — Mesenchymal Stem Cells: Time to Change the Name!. Stem cells translational medicine, 2017. DOI: 10.1002/sctm.17-0051.

  2. A Nature comment by Sipp, Robey and Turner arguing that loose use of 'mesenchymal stem cell' across an enormous range of unrelated cell preparations has produced a scientific and commercial mess, and calling for the terminology and the evidentiary standards to be tightened. Included because the objection to the word comes from inside stem cell science, not from its critics.

    Sipp D, et al. — Clear up this stem-cell mess.. Nature, 2018. DOI: 10.1038/d41586-018-06756-9.

  3. A dual systematic review compared the RCT evidence on injectable orthobiologics for knee OA with how news media describe it. Of 14 qualifying RCTs, 8 showed significant pain improvement and 10 function improvement, with frequent heterogeneity and risk of bias. Of 124 news articles: 79.0% highlighted benefits, only 29.8% mentioned drawbacks, 37.1% used the term 'stem cell' without specifying the product, 35.5% mentioned commercial entities with no disclosure, and 66.1% were favourable in tone. The authors conclude this disconnect encourages unrealistic expectations.

    Zhang EJX, et al. — Disparities in Evidence and Media Portrayal of Injectable Orthobiologics for Knee Osteoarthritis: A Systematic Review of Randomized Trials and News Media.. Orthopaedic journal of sports medicine, 2026. DOI: 10.1177/23259671261443876.

  4. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX at Level III evidence or higher (4 Level II, 2 Level III), covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment - meaning no consensus exists on indications, cell sources, preparation or delivery. Two products called 'stem cell therapy' at two clinics may share almost nothing.

    Chahla J, et al. — Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.. The Journal of bone and joint surgery. American volume, 2016. DOI: 10.2106/JBJS.15.01495.

  5. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected.

    Nakagawa HF, et al. — Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.. The American journal of sports medicine, 2025. DOI: 10.1177/03635465241249996.

  6. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

    US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.

  7. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

    Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

Would an exam help with the next choice?

QC Kinetix in Chandler can examine your hip and explain its non-surgical regenerative care. Medical providers means the licensed staff doing your exam and treatment; they prepare blood or marrow—soft tissue within bone—and guide that material to a sore joint or tendon.

The address is 1100 S. Dobson Rd., Suite 210, Chandler, AZ 85286. Call (602) 837-PAIN to discuss scheduling and your route from Queen Creek.

Schedule a free consultation